Calibration and discriminatory accuracy of prognosis calculation for breast cancer with the online Adjuvant! program: a hospital-based retrospective cohort study

The Lancet Oncology

Volumn 10, Issue 11, 2009, Pages 1070-1076

  Mook, Stella ^a   Schmidt, Marjanka K ^a   Rutgers, Emiel J ^a   van de Velde, Anthonie O ^a   Visser, Otto ^b   Rutgers, Sterre M ^a   Armstrong, Nicola ^a   van't Veer, Laura J ^a   Ravdin, Peter M ^c  

^a ANTONI VAN LEEUWENHOEK HOSPITAL   (Netherlands)

^b Integraal Kankercentrum Amsterdam   (Netherlands)

^c UNIVERSITY OF TEXAS HEALTH SCIENCE CENTER AT SAN ANTONIO   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLOPHOSPHAMIDE; DOXORUBICIN; EPIRUBICIN; FLUOROURACIL; METHOTREXATE; TAMOXIFEN;

ADJUVANT THERAPY; ADULT; AGED; ARTICLE; BREAST CANCER; CALIBRATION; CANCER ADJUVANT THERAPY; CANCER MORTALITY; CANCER SURVIVAL; COHORT ANALYSIS; COMPUTER PROGRAM; DISCRIMINANT VALIDITY; FEMALE; HUMAN; MAJOR CLINICAL STUDY; NETHERLANDS; PRIORITY JOURNAL; PROGNOSIS; SURVIVAL RATE; SURVIVAL TIME;

ADULT; AGE FACTORS; AGED; ANTINEOPLASTIC AGENTS; BREAST NEOPLASMS; CALIBRATION; CHEMOTHERAPY, ADJUVANT; DECISION SUPPORT TECHNIQUES; DISCRIMINANT ANALYSIS; DISEASE-FREE SURVIVAL; FEMALE; HOSPITALIZATION; HUMANS; INTERNET; KAPLAN-MEIER ESTIMATE; LYMPHATIC METASTASIS; MIDDLE AGED; MODELS, BIOLOGICAL; NEOPLASM STAGING; NETHERLANDS; ONLINE SYSTEMS; PATIENT SELECTION; PRACTICE GUIDELINES AS TOPIC; PREDICTIVE VALUE OF TESTS; PROPORTIONAL HAZARDS MODELS; RECEPTORS, ESTROGEN; REGISTRIES; REPRODUCIBILITY OF RESULTS; RETROSPECTIVE STUDIES; RISK ASSESSMENT; TIME FACTORS; TREATMENT OUTCOME;

EID: 71249163835     PISSN: 14702045     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1470-2045(09)70254-2     Document Type: Article

References (30)

1. NCCN Clinical practice guidelines in oncology: breast cancer V.I.2009. http://www.nccn.org/index.asp (accessed June 2, 2009).
2. Eifel P., Axelson J.A., Costa J., et al. National Institutes of Health consensus development conference statement: adjuvant therapy for breast cancer, November 1-3, 2000. J Natl Cancer Inst 93 (2001) 979-989
3. Goldhirsch A., Glick J.H., Gelber R.D., Coates A.S., and Senn H.J. Meeting highlights: international consensus panel on the treatment of primary breast cancer. J Clin Oncol 19 (2001) 3817-3827
4. Haybittle J.L., Blamey R.W., Elston C.W., et al. A prognostic index in primary breast cancer. Br J Cancer 45 (1982) 361-366
5. Galea M.H., Blamey R.W., Elston C.E., and Ellis I.O. The Nottingham Prognostic Index in primary breast cancer. Breast Cancer Res Treat 22 (1992) 207-219
6. Ravdin P.M., Siminoff L.A., Davis G.J., et al. Computer program to assist in making decisions about adjuvant therapy for women with early breast cancer. J Clin Oncol 19 (2001) 980-991
7. Early Breast Cancer Trialists' Collaborative Group. Polychemotherapy for early breast cancer: an overview of the randomised trials. Lancet 352 (1998) 930-942
8. Early Breast Cancer Trialists' Collaborative Group. Tamoxifen for early breast cancer: an overview of the randomised trials. Lancet 351 (1998) 1451-1467
9. Early Breast Cancer Trialists' Collaborative Group. Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials. Lancet 365 (2005) 1687-1717
10. Siminoff L.A., Gordon N.H., Silverman P., Budd T., and Ravdin P.M. A decision aid to assist in adjuvant therapy choices for breast cancer. Psychooncology 15 (2006) 1001-1013
11. Zikmund-Fisher B.J., Fagerlin A., and Ubel P.A. Improving understanding of adjuvant therapy options by using simpler risk graphics. Cancer 113 (2008) 3382-3390
12. Belkora J.K., Rugo H.S., Moore D.H., et al. Oncologist use of the Adjuvant! model for risk communication: a pilot study examining patient knowledge of 10-year prognosis. BMC Cancer 9 (2009) 127-134
13. Olivotto I.A., Bajdik C.D., Ravdin P.M., et al. Population-based validation of the prognostic model ADJUVANT! for early breast cancer. J Clin Oncol 23 (2005) 2716-2725
14. Coleman M.P., Quaresma M., Berrino F., et al. Cancer survival in five continents: a worldwide population-based study (CONCORD). Lancet Oncol 9 (2008) 730-756
15. Sant M., Allemani C., Berrino F., et al. Breast carcinoma survival in Europe and the United States. Cancer 100 (2004) 715-722
16. Chlebowski R.T., Aiello E., and McTiernan A. Weight loss in breast cancer patient management. J Clin Oncol 20 (2002) 1128-1143
17. Kwaliteitsorgaan voor Gezondheidszorg CBO, Nationaal Borstkanker Overleg Nederland NABON, Richtlijn Behandeling van het Mammacarcinoom 2008. http://www.cbo.nl/product/richtlijnen/folder20021023121843/rl_mamma_08.pdf (accessed June 2, 2009).
18. Harlan L.C., Clegg L.X., Abrams J., Stevens J.L., and Ballard-Barbash R. Community-based use of chemotherapy and hormonal therapy for early-stage breast cancer: 1987-2000. J Clin Oncol 24 (2006) 872-877
19. Chlebowski R.T., Chen Z., Anderson G.L., et al. Ethnicity and breast cancer: factors influencing differences in incidence and outcome. J Natl Cancer Inst 97 (2005) 439-448
20. Love N. Management of breast cancer in the adjuvant and metastatic settings: patterns of care in medical oncology. http://www.paternsofcare.com/2005/3/adjuvant.htm (accessed June 2, 2009).
21. Bogaerts J., Cardoso F., Buyse M., et al. Gene signature evaluation as a prognostic tool: challenges in the design of the MINDACT trial. Nat Clin Pract Oncol 3 (2006) 540-551
22. Cardoso F., Van't Veer L., Rutgers E., et al. Clinical application of the 70-gene profile: the MINDACT trial. J Clin Oncol 26 (2008) 729-735
23. Harrell Jr. F.E., Lee K.L., and Mark D.B. Multivariable prognostic models: issues in developing models, evaluating assumptions and adequacy, and measuring and reducing errors. Stat Med 15 (1996) 361-387
24. Schemper M., and Henderson R. Predictive accuracy and explained variation in Cox regression. Biometrics 56 (2000) 249-255
25. Von Elm E., Altman D.G., Egger M., et al. The strengthening the reporting of observational studies in epidemiology (STROBE) statement: guidelines for reporting observational studies. Lancet 370 (2007) 1453-1457
26. Kaplan E.L., and Meier P. Nonparametric estimation from incomplete observation. J Am Stat Assoc 53 (1958) 457-481
27. Cox D.R. Regression models and lifetables. J R Statist Soc B 34 (1972) 187-220
28. Pedersen L., Holck S., Schiodt T., Zedeler K., and Mouridsen H.T. Medullary carcinoma of the breast, prognostic importance of characteristic histopathological features evaluated in a multivariate Cox analysis. Eur J Cancer 30A (1994) 1792-1797
29. Cote R.J., Peterson H.F., Chaiwun B., et al. Role of immunohistochemical detection of lymph-node metastases in management of breast cancer. Lancet 354 (1999) 896-900
30. Reed J., Rosman M., Verbanac K., et al. Prognostic implications of isolated tumour cells and micrometastases in sentinel nodes of patients with invasive breast cancer: 10-year analysis of patients enrolled in the prospective east Carolina University/Anne Arundel Medical Center sentinel node multicenter study. J Am Coll Surg 208 (2009) 333-340